07:00 , Apr 7, 2014 |  BioCentury  |  Finance

2Q14 Financial Markets Preview: Big buying opps

Buysiders say a steady flow of positive news could play a critical role in reinvigorating investor interest in biotech, and are especially watchful for news from Gilead Sciences Inc. , Vertex Pharmaceuticals Inc. and companies...
08:00 , Dec 20, 2010 |  BC Week In Review  |  Company News

Merck, PATH Malaria Vaccine Initiative, New York University deal

PATH and Merck partnered with the university to develop a vaccine targeting Plasmodium falciparum circumsporozoite (CS) protein (CSP) to prevent malaria. PATH will provide financial support, Merck will design and optimize the vaccine compounds and...
07:00 , Sep 6, 2010 |  BC Week In Review  |  Clinical News

Herpes zoster vaccine: Phase III started

GSK began the double-blind, placebo-controlled, international Phase III Zoster-006 trial to evaluate intramuscular herpes zoster vaccine in 27,400 patients ages 50 and older. The vaccine contains the QS-21 Stimulon adjuvant from Antigenics Inc. (NASDAQ:AGEN, Lexington,...
07:00 , Sep 6, 2010 |  BC Week In Review  |  Clinical News

Herpes zoster vaccine: Phase III started

GSK began the double-blind, placebo-controlled, international Phase III Zoster-022 trial to evaluate intramuscular herpes zoster vaccine in 11,000 patients ages 70 and older. The vaccine contains the QS-21 Stimulon adjuvant from Antigenics Inc. (NASDAQ:AGEN, Lexington,...
07:00 , Aug 2, 2010 |  BC Week In Review  |  Clinical News

AG-707: Phase I data

Top-line data from a dose-escalation Phase I trial in 35 patients showed that AG-707 was well tolerated, with injection site pain reported as the most common adverse event. Additionally, AG-707 plus Antigenics' QS-21 Stimulon adjuvant...
07:00 , Jul 26, 2010 |  BC Week In Review  |  Financial News

Antigenics financial update

Antigenics received a letter from NASDAQ indicating the company is not in compliance with the $1 minimum bid price requirement for continued listing. The company has until Jan. 18 to regain compliance. Antigenics Inc. (NASDAQ:AGEN),...
07:00 , May 24, 2010 |  BC Week In Review  |  Clinical News

Oncophage vitespen: Additional Phase I/II data

Additional data from 32 evaluable patients with recurrent high-grade glioma in an open-label, U.S. Phase I/II trial showed that Oncophage resulted in an overall median survival of 44 weeks following tumor resection. Additionally, 70% and...
07:00 , Apr 12, 2010 |  BC Week In Review  |  Company News

Crucell, GlaxoSmithKline deal

Crucell and GSK partnered to develop a second-generation malaria vaccine . Crucell will contribute its AdVac Ad35-CS recombinant malaria vaccine, and GSK will contribute its Mosquirix malaria vaccine. Ad35-CS, which is based on Crucell's AdVac...
07:00 , Apr 12, 2010 |  BioCentury  |  Finance

Regulatory Milestones

Cell Therapeutics Inc. (NASDAQ:CTIC; Milan:CTIC) gained $0.09 (18%) to $0.63 last week after FDA issued a complete response letter for an NDA for Pixuvri pixantrone to treat relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). The...
00:51 , Apr 7, 2010 |  BC Extra  |  Company News

Crucell, GSK to develop malaria vaccine

Crucell N.V. (Euronext:CRXL; NASDAQ:CRXL) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) partnered to develop a second-generation malaria vaccine. Crucell will contribute its AdVac Ad35-CS recombinant malaria vaccine, and GSK will contribute its Mosquirix malaria vaccine. Ad35-CS, which...